share_log

Avalo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nantahala Capital Management, LLC(4.9%),Wilmot B. Harkey(4.9%), etc.

SEC announcement ·  Feb 14 16:58
Summary by Moomoo AI
Avalo Therapeutics, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated December 31, 2023, was submitted by Nantahala Capital Management, LLC, along with individuals Wilmot B. Harkey and Daniel Mack, collectively referred to as the Reporting Persons. According to the document, each of the Reporting Persons may be deemed to beneficially own 42,100 shares of Avalo Therapeutics, which represents 4.9% of the company's outstanding common stock. The filing also notes that the Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock. The shares are held by funds and accounts under the control of...Show More
Avalo Therapeutics, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated December 31, 2023, was submitted by Nantahala Capital Management, LLC, along with individuals Wilmot B. Harkey and Daniel Mack, collectively referred to as the Reporting Persons. According to the document, each of the Reporting Persons may be deemed to beneficially own 42,100 shares of Avalo Therapeutics, which represents 4.9% of the company's outstanding common stock. The filing also notes that the Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock. The shares are held by funds and accounts under the control of Nantahala Capital Management, with Harkey and Mack having shared voting and dispositive power over these shares. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, with Nantahala Capital Management identified as an investment adviser and Harkey and Mack as control persons. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Avalo Therapeutics.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more